Background: Buprenorphine is a key tool in the management of opioid use disorder, but there are growing concerns about abuse, diversion, and safety. These concerns are amplified for the Department of Veterans Affairs (VA), whose patients may receive care concurrently from multiple prescribers within and outside VA. To illustrate the extent of this challenge, we examined overlapping prescriptions for buprenorphine, opioids, and benzodiazepines among veterans dually enrolled in VA and Medicare Part D.
Methods: We constructed a cohort of all veterans dually enrolled in VA and Part D who filled an opioid prescription in 2012. We identified patients who received tablet or film buprenorphine products from either source. We calculated the proportion of buprenorphine recipients with any overlapping prescription (based on days supply) for a nonbuprenorphine opioid or benzodiazepine, focusing on veterans who received overlapping prescriptions from a different system than their buprenorphine prescription (Part D buprenorphine recipients receiving overlapping opioids or benzodiazepines from VA and vice versa).
Results: There were 1790 dually enrolled veterans with buprenorphine prescriptions, including 760 (43%) from VA and 1091 (61%) from Part D (61 veterans with buprenorphine from both systems were included in each group). Among VA buprenorphine recipients, 199 (26%) received an overlapping opioid prescription and 11 (1%) received an overlapping benzodiazepine prescription from Part D. Among Part D buprenorphine recipients, 208 (19%) received an overlapping opioid prescription and 178 (16%) received an overlapping benzodiazepine prescription from VA. Among VA and Part D buprenorphine recipients with cross-system opioid overlap, 25% (49/199) and 35% (72/208), respectively, had >90 days of overlap.
Conclusions: Many buprenorphine recipients receive overlapping prescriptions for opioids and benzodiazepines from a different health care system than the one in which their buprenorphine was filled. These findings highlight a previously undocumented safety risk for veterans dually enrolled in VA and Medicare.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315586 | PMC |
| http://dx.doi.org/10.1080/08897077.2016.1267071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder.
Nat Ment Health
July 2024
Department of Family/Community Medicine and Health and Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA.
While attention deficit hyperactivity disorder is common among people with addiction, the risks and benefits of attention deficit hyperactivity disorder medication in pregnant people with opioid use disorder are poorly understood. Here, using US multistate administrative data, we examined 3,247 pregnant people initiating opioid use disorder treatment, of whom 5% received psychostimulants. Compared to peers not receiving psychostimulants, the psychostimulant cohort had greater buprenorphine (adjusted relative risk 1.
View Article and Find Full Text PDFBuprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.
JAMA
December 2024
British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Article Synopsis
- Previous studies showed limited evidence on how buprenorphine versus methadone affects different groups of people using opioids, particularly with the rise of fentanyl use.
- The study aimed to compare the risks of treatment discontinuation and mortality between individuals using buprenorphine/naloxone versus those using methadone for opioid use disorder in British Columbia from 2010 to 2020.
- Findings revealed that users of buprenorphine/naloxone had a significantly higher likelihood of discontinuing treatment after 24 months compared to those on methadone, with 88.8% versus 81.5% discontinuing, indicating that methadone may be more effective in retaining users.
Healthcare utilisation and associated costs for methadone versus buprenorphine recipients: Examination of interlinked primary and secondary care electronic health records in England.
Drug Alcohol Rev
November 2024
National Institute for Health and Care Research Greater Manchester Patient Safety Research Collaboration, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Introduction: More evidence for patterns of healthcare utilisation and associated costs among people receiving opioid agonist therapy (OAT) is needed. We investigated primary and secondary healthcare usage and costs among methadone and buprenorphine recipients in England.
Methods: We conducted a cohort study using the Clinical Practice Research Datalink GOLD and Aurum databases of patients who were prescribed OAT between 1 January 2007 and 31 July 2019.
Self-help groups and opioid use disorder treatment: An investigation using a machine learning-assisted robust causal inference framework.
Int J Med Inform
October 2024
Dept. of Mechanical and Industrial Engineering, College of Engineering, Northeastern University, 360 Huntington Avenue, Boston, MA 02135, USA. Electronic address:
Objectives: This study investigates the impact of participation in self-help groups on treatment completion among individuals undergoing medication for opioid use disorder (MOUD) treatment. Given the suboptimal adherence and retention rates for MOUD, this research seeks to examine the association between treatment completion and patient-level factors. Specifically, we evaluated the causal relationship between self-help group participation and treatment completion for patients undergoing MOUD.
View Article and Find Full Text PDF'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.
Int J Drug Policy
July 2024
National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8BB, UK; South London & Maudsley (SLaM) NHS Foundation Trust, London SE5 8AZ, UK.
Article Synopsis
- Discontinuation of long-acting injectable buprenorphine (LAIB) among patients in opioid agonist treatment is a complex issue influenced by various factors, including both provider decisions and patient choices.
- A longitudinal qualitative study consisting of 44 interviews with 8 participants revealed that factors like late appointments, substance use, personal circumstances, and treatment side effects significantly contribute to prescription discontinuation.
- The findings highlight that opioid agonist treatment is not a one-size-fits-all solution; it evolves based on individual experiences and motivations, indicating a need for flexible treatment approaches.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!